Diabesity is a growing pandemic with substantial health and financial consequences. We are developing microRNA (miRNA)-based drug candidates that transform fat storing adipocytes into fat burning adipocytes (browning effect) to treat metabolic diseases characterized by lipotoxicity. Through phenotypic screening in primary cultures of human subcutaneous adipocytes, we discovered that inhibition of miRNA-22-3p by several complementary antagomirs resulted in increased lipid oxidation, mitochondrial activity, and energy expenditure (EE). These effects may be mediated through activation of target genes like KDM3A, KDM6B, PPARA, PPARGC1B, and SIRT1 involved in lipid catabolism, thermogenesis, and glucose homeostasis. In the model of Diet-Induced Obesity in mice of various ages, weekly subcutaneous injections of various miRNA-22-3p antagomirs produced a significant fat mass reduction, but no change of appetite or body temperature. Insulin sensitivity, as well as circulating glucose and cholesterol levels, was also improved. These original findings suggest that miRNA-22-3p inhibition could become a potent treatment of human obesity and type 2 diabetes mellitus, the so-called diabesity characterized by lipotoxicity and insulin resistance.
Get full access to this article
View all access options for this article.
References
1.
NgM, FlemingT, RobinsonM, ThomsonB, GraetzN, MargonoC, MullanyEC, BiryukovS, AbbafatiC, et al. (2014). Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 384:766–781.
2.
HaslamDW and JamesWP. (2005). Obesity. Lancet, 366:1197–1209.
3.
JensenMD, RyanDH, ApovianCM, ArdJD, ComuzzieAG, DonatoKA, HuFB, HubbardVS, JakicicJM, et al. (2014). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation, 129:S102–S138.
4.
ColmanE, GoldenJ, RobertsM, EganA, WeaverJ, and RosebraughC. (2012). The FDA's assessment of two drugs for chronic weight management. N Engl J Med, 367:1577–1579.
5.
CohenP and SpiegelmanBM. (2015). Brown and beige fat: molecular parts of a thermogenic machine. Diabetes, 64:2346–2351.
6.
SharpLZ, ShinodaK, OhnoH, ScheelDW, TomodaE, RuizL, HuH, WangL, PavlovaZ, V, et al. (2012). Human BAT possesses molecular signatures that resemble beige/brite cells. PLoS One, 7:e49452.
7.
CereijoR, GiraltM and VillarroyaF. (2015). Thermogenic brown and beige/brite adipogenesis in humans. Ann Med, 47:169–177.
8.
WuJ, CohenP and SpiegelmanBM. (2013). Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev, 27:234–250.
9.
KozakLP and Anunciado-KozaR. (2008). UCP1: its involvement and utility in obesity. Int J Obes, 32(Suppl. 7):S32–S38.
10.
HarmsM and SealeP. (2013). Brown and beige fat: development, function and therapeutic potential. Nat Med, 19:1252–1263.
11.
SidossisL and KajimuraS. (2015). Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis. J Clin Invest, 125:478–486.
12.
ChechiK, NedergaardJ and RichardD. (2014). Brown adipose tissue as an anti-obesity tissue in humans. Obes Rev, 15:92–106.
13.
KimSH and PlutzkyJ. (2016). Brown fat and browning for the treatment of obesity and related metabolic disorders. Diabetes Metab J, 40:12–21.
14.
RicquierD and BouillaudF. (2000). The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP. Biochem J, 345(Pt 2):161–179.
15.
RoussetS, Alves-GuerraMC, MozoJ, MirouxB, Cassard-DoulcierAM, BouillaudF and RicquierD. (2004). The biology of mitochondrial uncoupling proteins. Diabetes, 53(Suppl. 1):S130–S135.
16.
CollinsS, Yehuda-ShnaidmanE and Wang.H (2010). Positive and negative control of Ucp1 gene transcription and the role of beta-adrenergic signaling networks. Int J Obes, 34(Suppl. 1):S28–S33.
17.
MozoJ, EmreY, BouillaudF, RicquierD and CriscuoloF. (2005). Thermoregulation: what role for UCPs in mammals and birds? Biosci Rep, 25:227–249.
18.
Del Mar Gonzalez-BarrosoM, RicquierD and Cassard-DoulcierAM. (2000). The human uncoupling protein-1 gene (UCP1): present status and perspectives in obesity research. Obes Rev, 1:61–72.
19.
ShoreA, KaramitriA, KempP, SpeakmanJR and LomaxMA. (2010). Role of Ucp1 enhancer methylation and chromatin remodelling in the control of Ucp1 expression in murine adipose tissue. Diabetologia, 53:1164–1173.
20.
TateishiK, OkadaY, KallinEM and ZhangY. (2009). Role of Jhdm2a in regulating metabolic gene expression and obesity resistance. Nature, 458:757–761.
21.
OkadaY, TateishiK and ZhangY. (2010). Histone demethylase JHDM2A is involved in male infertility and obesity. J Androl, 31:75–78.
22.
AbeY, RozqieR, MatsumuraY, KawamuraT, NakakiR, TsurutaniY, Tanimura-InagakiK, ShionoA, MagooriK, et al. (2015). JMJD1A is a signal-sensing scaffold that regulates acute chromatin dynamics via SWI/SNF association for thermogenesis. Nat Commun, 6:7052.
23.
ShuaiY, YangR, MuR, YuY, RongL and JinL. (2019). MiR-199a-3p mediates the adipogenic differentiation of bone marrow-derived mesenchymal stem cells by regulating KDM6A/WNT signaling. Life Sci, 220:84–91.
24.
SakamotoA, HinoS, NagaokaK, AnanK, TakaseR, MatsumoriH, OjimaH, KanaiY, AritaK and NakaoM. (2015). Lysine demethylase LSD1 coordinates glycolytic and mitochondrial metabolism in hepatocellular carcinoma cells. Cancer Res, 75:1445–1456.
TanimuraK, SuzukiT, VargasD, ShibataH and InagakiT. (2019). Epigenetic regulation of beige adipocyte fate by histone methylation. Endocr J, 66:115–125.
27.
van Rooij E and KauppinenS. (2014). Development of microRNA therapeutics is coming of age. EMBO Mol Med, 6:851–864.
28.
HiltonC, NevilleMJ and KarpeF. (2012). MicroRNAs in adipose tissue: their role in adipogenesis and obesity. Int J Obes (Lond), 37:325–332.
29.
InuiM, MartelloG and PiccoloS. (2010). MicroRNA control of signal transduction. Nat Rev Mol Cell Biol, 11:252–263.
30.
KanasakiK and Koya.D (2011). Biology of obesity: lessons from animal models of obesity. J Biomed Biotechnol, 2011:197636.
31.
LiangY, RidzonD, WongL and Chen.C (2007). Characterization of microRNA expression profiles in normal human tissues. BMC Genomics, 8:166.
32.
EguchiA, LazicM, ArmandoAM, PhillipsSA, KatebianR, MarakaS, QuehenbergerO, SearsDD and FeldsteinAE. (2016). Circulating adipocyte-derived extracellular vesicles are novel markers of metabolic stress. J Mol Med (Berl), 94:1241–1253.
33.
YingW, RiopelM, BandyopadhyayG, DongY, BirminghamA, SeoJB, OfrecioJM, WollamJ, Hernandez-CarreteroA, et al. (2017). Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell, 171:372–384.e312.
34.
CastanoC, KalkoS, NovialsA and ParrizasM. (2018). Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice. Proc Natl Acad Sci U S A, 115:12158–12163.
35.
HondaresE, RosellM, Diaz-DelfinJ, OlmosY, MonsalveM, IglesiasR, VillarroyaF and GiraltM. (2011). PPARalpha induces PGC-1alpha gene expression and contributes to the thermogenic activation of brown fat; involvement of PRDM16. J Biol Chem, 286:43112–43122.
36.
XueB, CoulterA, RimJS, Koza, RA and KozakLP. (2005). Transcriptional synergy and the regulation of Ucp1 during brown adipocyte induction in white fat depots. Mol Cell Biol, 25:8311–8322.
37.
LanginD. (2010). Recruitment of brown fat and conversion of white into brown adipocytes: strategies to fight the metabolic complications of obesity? Biochim Biophys Acta, 1801:372–376.
38.
RibetC, MontastierE, ValleC, BezaireV, MazzucotelliA, MairalA, Viguerie, N and LanginD. (2010). Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes. Endocrinology, 151:123–133.
39.
YamagataK and YoshizawaT. (2018). Transcriptional regulation of metabolism by SIRT1 and SIRT7. Int Rev Cell Mol Biol, 335:143–166.
40.
BartesaghiS, HallenS, HuangL, SvenssonPA, MomoRA, WallinS, CarlssonEK, ForslowA, SealeP and PengXR. (2015). Thermogenic activity of UCP1 in human white fat-derived beige adipocytes. Mol Endocrinol, 29:130–139.
41.
PriceNL and Fernandez-HernandoC. (2016). miRNA regulation of white and brown adipose tissue differentiation and function. Biochim Biophys Acta, 1861(12 Pt B):2104–2110.
42.
XieH, SunL and LodishHF. (2009). Targeting microRNAs in obesity. Expert Opin Ther Targets, 13:1227–1238.
43.
ArnerP and KulyteA. (2015). MicroRNA regulatory networks in human adipose tissue and obesity. Nat Rev Endocrinol, 11:276–288.
44.
AbenteEJ, SubramanianM, RamachandranV and Najafi-ShoushtariSH. (2016). MicroRNAs in obesity-associated disorders. Arch Biochem Biophys, 589:108–119.
45.
ZhuH and LeungSW. (2015). Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies. Diabetologia, 58:900–911.
46.
SonYH, KaS, KimAY and KimJB. (2014). Regulation of adipocyte differentiation via microRNAs. Endocrinol Metab (Seoul), 29:122–135.
47.
LiZ and RanaTM. (2014). Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov, 13:622–638.
48.
HannaJ, HossainGS and KocerhaJ.. (2019). The potential for microRNA therapeutics and clinical research. Front Genet, 10:478.
49.
ThomouT, MoriMA, DreyfussJM, KonishiM, SakaguchiM, WolfrumC, RaoTN, WinnayJN, Garcia-MartinR, et al. (2017). Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature, 542:450–455.
50.
LeeMW, LeeM and Oh.KJ (2019). Adipose tissue-derived signatures for obesity and type 2 diabetes: adipokines, batokines and microRNAs. J Clin Med, 8:E854.
51.
ZhangLN, GamoY, SinclairR, MitchellSE, MorganDG, ClaphamJC and SpeakmanJR. (2012). Effects of chronic oral rimonabant administration on energy budgets of diet-induced obese C57BL/6 mice. Obesity (Silver Spring), 20:954–962.
52.
GurhaP, WangT, LarimoreAH, SassiY, Abreu-GoodgerC, RamirezMO, ReddyAK, EngelhardtS, TaffetGE, et al. (2013). microRNA-22 promotes heart failure through coordinate suppression of PPAR/ERR-nuclear hormone receptor transcription. PLoS One, 8:e75882.
53.
KurylowiczA, OwczarzM, PolosakJ, JonasMI, LisikW, JonasM, ChmuraA and Puzianowska-KuznickaM. (2016). SIRT1 and SIRT7 expression in adipose tissues of obese and normal-weight individuals is regulated by microRNAs but not by methylation status. Int J Obes (Lond), 40:1635–1642.
54.
DuJK, CongBH, YuQ, WangH, WangL, WangCN, TangXL, LuJQ, ZhuXY and NiX. (2016). Upregulation of microRNA-22 contributes to myocardial ischemia-reperfusion injury by interfering with the mitochondrial function. Free Radic Biol Med, 96:406–417.
55.
DinizGP, HuangZP, LiuJ, ChenJ, DingJ, FonsecaRI, Barreto-ChavesML, Donato JrJ., HuX and WangDZ. (2017). Loss of microRNA-22 prevents high-fat diet induced dyslipidemia and increases energy expenditure without affecting cardiac hypertrophy. Clin Sci, 131:2885–2900.
56.
SchweisgutJ, SchuttC, WustS, WietelmannA, GhesquiereB, CarmelietP, DroseS, KorachKS, BraunT and BoettgerT. (2017). Sex-specific, reciprocal regulation of ERalpha and miR-22 controls muscle lipid metabolism in male mice. EMBO J, 36:1199–1214.
57.
KaurK, VigS, SrivastavaR, MishraA, SinghVP, SrivastavaAK and DattaM. (2015). Elevated hepatic miR-22-3p expression impairs gluconeogenesis by silencing the Wnt-responsive transcription factor Tcf7. Diabetes, 64:3659–3669.
58.
KaurK, PandeyAK, SrivastavaS, SrivastavaAK and DattaM. (2011). Comprehensive miRNome and in silico analyses identify the Wnt signaling pathway to be altered in the diabetic liver. Mol Biosyst, 7:3234–3244.
59.
ZhangX, PriceNL and Fernandez-HernandoC. (2019). Non-coding RNAs in lipid metabolism. Vascul Pharmacol, 114:93–102.
60.
AlrobOA, KhatibS and NaserSA. (2017). MicroRNAs 33, 122, and 208: a potential novel targets in the treatment of obesity, diabetes, and heart-related diseases. J Physiol Biochem, 73:307–314.
61.
ZaiouM, El AmriH and BakillahA. (2018). The clinical potential of adipogenesis and obesity-related microRNAs. Nutr Metab Cardiovasc Dis, 28:91–111.
62.
SeegerT, FischerA, Muhly-ReinholzM, ZeiherAM and DimmelerS. (2014). Long-term inhibition of miR-21 leads to reduction of obesity in db/db mice. Obesity (Silver Spring), 22:2352–2360.
63.
LidellME and EnerbackS. (2010). Brown adipose tissue—a new role in humans? Nat Rev Endocrinol, 6:319–325.
64.
AlgireC, MedrikovaD and HerzigS. (2013). White and brown adipose stem cells: from signaling to clinical implications. Biochim Biophys Acta, 1831:896–904.
65.
CannonB and NedergaardJ. (2012). Yes, even human brown fat is on fire! J Clin Invest, 122:486–489.
66.
CeliFS, LeTN and NiB. (2015). Physiology and relevance of human adaptive thermogenesis response. Trends Endocrinol Metab, 26:238–247.
67.
LeeP, SwarbrickMM and HoKK. (2013). Brown adipose tissue in adult humans: a metabolic renaissance. Endocr Rev, 34:413–438.
68.
NedergaardJ and CannonB. (2010). The changed metabolic world with human brown adipose tissue: therapeutic visions. Cell Metab, 11:268–272.
69.
BonetML, OliverP and PalouA. (2013). Pharmacological and nutritional agents promoting browning of white adipose tissue. Biochim Biophys Acta, 1831:969–985.
70.
LowellBB and SpiegelmanBM. (2000). Towards a molecular understanding of adaptive thermogenesis. Nature, 404:652–660.
71.
KozakLP. (2010). Brown fat and the myth of diet-induced thermogenesis. Cell Metab, 11:263–267.
72.
VosselmanMJ, van Marken LichtenbeltWD and SchrauwenP. (2013). Energy dissipation in brown adipose tissue: from mice to men. Mol Cell Endocrinol, 379:43–50.
73.
GrundlinghJ, DarganPI, El-ZanfalyM and WoodDM. (2011). 2,4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death. J Med Toxicol, 7:205–212.
74.
LinJZ, MartagonAJ, CiminiSL, GonzalezDD, TinkeyDW, BiterA, BaxterJD, WebbP, GustafssonJA, et al. (2015). Pharmacological activation of thyroid hormone receptors elicits a functional conversion of white to brown fat. Cell Rep, 13:1528–1537.
75.
ArchJR. (2011). Challenges in beta(3)-adrenoceptor agonist drug development. Ther Adv Endocrinol Metab, 2:59–64.
76.
CypessAM, WeinerLS, Roberts-TolerC, Franquet EliaE, KesslerSH, KahnPA, EnglishJ, ChatmanK, TraugerSA, et al. (2015). Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist. Cell Metab, 21:33–38.
77.
PerryRJ, KimT, ZhangXM, LeeHY, PestaD, PopovVB, ZhangD, RahimiY, JurczakMJ, et al. (2013). Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. Cell Metab, 18:740–748.
78.
TaoH, ZhangY, ZengX, ShulmanGI and JinS. (2014). Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. Nat Med, 20:1263–1269.
79.
SaitoM. (2015). Capsaicin and related food ingredients reducing body fat through the activation of TRP and brown fat thermogenesis. Adv Food Nutr Res, 76:1–28.
80.
StanfordKI, MiddelbeekRJ, TownsendKL, AnD, NygaardEB, HitchcoxKM, MarkanKR, NakanoK, HirshmanMF, et al. (2013). Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest, 123:215–223.
81.
CapozziME, DiMarchiRD, TschopMH, FinanB and CampbellJE. (2018). Targeting the incretin/glucagon system with triagonists to treat diabetes. Endocr Rev, 39:719–738.
82.
BeharyP, TharakanG, AlexiadouK, JohnsonN, Wewer AlbrechtsenNJ, KenkreJ, CuencoJ, HopeD, AnyiamO, et al. (2019). Combined GLP-1, oxyntomodulin, and peptide YY improves body weight and glycemia in obesity and prediabetes/type 2 diabetes: a randomized, single-blinded, placebo-controlled study. Diabetes Care, 42:1446–1453.
83.
KokkinosA, TsilingirisD, le RouxCW, RubinoF and MantzorosCS. (2019). Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?. Metabolism, 100:153960.
84.
AlexiadouK, AnyiamO and Tan.T (2019). Cracking the combination: gut hormones for the treatment of obesity and diabetes. J Neuroendocrinol, 31:e12664.
85.
CoskunT, SloopKW, LoghinC, Alsina-FernandezJ, UrvaS, BokvistKB, CuiX, BriereDA, CabreraO, et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab, 18:3–14.
86.
FriasJP, NauckMA, VanJ, KutnerME, CuiX, BensonC, UrvaS, GimenoRE, MilicevicZ, et al. (2018). Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet, 392:2180–2193.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
